Vol 50 No 03

Learning curve for technique is short, but capital expenditures are required.

"The future is bright for immunotherapy in bladder cancer," writes Michael S. Cookson, MD, MMHC.

"I use PSA testing to make sure patients with high-risk prostate cancer, specifically, and advanced prostate cancer, or even metastatic prostate cancer, don’t go undiagnosed," says 1 urologist.

"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.

Payer edits referencing ICD-10-CM guidelines such as “Excludes 1” are on the rise.

Plaintiff claims defendant negligently failed to order urology consult.

Having a year-to-year strategy helps you achieve short- and long-term goals.

“Such findings underscore the need for and importance of molecular testing to inform management along with continued research to establish treatment paradigms with appropriately targeted therapies for patients with prostate cancer,” the authors wrote.

Think of the forgotten stent primarily as a patient safety issue, writes Robert A. Dowling, MD.

“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.

“Patients are overwhelmed by these choices often, and don't really understand the risks and benefits when they're first told about them,” said co-author Anjali Kapur, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Howard Goldman, MD, discusses the development of the midurethral sling as a treatment for stress urinary incontinence.

In this interview, Brant A. Inman, MD, MS, FRCSC, discusses how investigational chemothermotherapy could mitigate some challenges presented by current NMIBC treatments.

Cost was the most commonly reported barrier to genetic testing.

Naomi B. Haas, MD, discusses efforts to improve care in locally advanced renal cell carcinoma through research in the neoadjuvant setting.

In a recent study presented at the 2021 SMSNA Fall Scientific Meeting, Jay Newmark, MD, MBA, and co-authors report promising findings on the first experiences of patients using JATENZO in the real world.